In draft guidance, NICE rebuffs Gilead's twice-a-year PrEP med for national coverage

In a move that at least one local HIV charity has deemed “profoundly disappointing,” England's health technology assessor NICE is currently recommending against coverage of Gilead Sciences’ landmar | In a move that at least one local HIV charity has deemed “profoundly disappointing,” England's health technology assessor NICE is currently recommending against coverage of Gilead Sciences’ landmark twice-a-year PrEP medication lenacapavir on the National Health Service.